KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to $470.0 million.

  • Eli Lilly's Depreciation & Amortization (CF) rose 68.55% to $470.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year increase of 1357.29%. This contributed to the annual value of $1.8 billion for FY2024, which is 1566.82% up from last year.
  • As of Q3 2025, Eli Lilly's Depreciation & Amortization (CF) stood at $470.0 million, which was up 68.55% from $478.5 million recorded in Q2 2025.
  • Eli Lilly's 5-year Depreciation & Amortization (CF) high stood at $484.8 million for Q4 2024, and its period low was $348.9 million during Q2 2022.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $400.6 million (2024), whereas its average is $409.2 million.
  • Per our database at Business Quant, Eli Lilly's Depreciation & Amortization (CF) soared by 2803.36% in 2021 and then tumbled by 1684.65% in 2023.
  • Eli Lilly's Depreciation & Amortization (CF) (Quarter) stood at $445.7 million in 2021, then decreased by 15.86% to $375.0 million in 2022, then rose by 3.39% to $387.7 million in 2023, then grew by 25.05% to $484.8 million in 2024, then dropped by 3.05% to $470.0 million in 2025.
  • Its last three reported values are $470.0 million in Q3 2025, $478.5 million for Q2 2025, and $462.8 million during Q1 2025.